Sanofi, Regeneron eye Dupixent label expansion with promising COPD data

Dupixent appears to have done it again.

The monoclonal antibody from Sanofi and Regeneron was successful in treating chronic obstructive pulmonary disease (COPD) in Phase 3 trial data unveiled Monday morning.